93 related articles for article (PubMed ID: 15000842)
1. chTNT-3/hu IL-12 fusion protein for the immunotherapy of experimental solid tumors.
Li J; Hu P; Khawli LA; Yun A; Epstein AL
Hybrid Hybridomics; 2004 Feb; 23(1):1-10. PubMed ID: 15000842
[TBL] [Abstract][Full Text] [Related]
2. Chimeric TNT-3 antibody/murine interferon-gamma fusion protein for the immunotherapy of solid malignancies.
Mizokami MM; Hu P; Khawli LA; Li J; Epstein AL
Hybrid Hybridomics; 2003 Aug; 22(4):197-207. PubMed ID: 14511565
[TBL] [Abstract][Full Text] [Related]
3. LEC/chTNT-3 fusion protein for the immunotherapy of experimental solid tumors.
Li J; Hu P; Khawli LA; Epstein AL
J Immunother; 2003; 26(4):320-31. PubMed ID: 12843794
[TBL] [Abstract][Full Text] [Related]
4. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion.
Li J; Hu P; Khawli LA; Epstein AL
Cancer Res; 2003 Dec; 63(23):8384-92. PubMed ID: 14679000
[TBL] [Abstract][Full Text] [Related]
5. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
Khawli LA; Hu P; Epstein AL
Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
[TBL] [Abstract][Full Text] [Related]
6. Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases.
Gillies SD; Lan Y; Wesolowski JS; Qian X; Reisfeld RA; Holden S; Super M; Lo KM
J Immunol; 1998 Jun; 160(12):6195-203. PubMed ID: 9637539
[TBL] [Abstract][Full Text] [Related]
7. Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy.
Liu M; Wang H; Liu L; Wang B; Sun G
J Transl Med; 2016 Jun; 14(1):155. PubMed ID: 27246873
[TBL] [Abstract][Full Text] [Related]
8. Gene therapy of anaplastic thyroid carcinoma with a single-chain interleukin-12 fusion protein.
Shi Y; Parhar RS; Zou M; Baitei E; Kessie G; Farid NR; Alzahrani A; Al-Mohanna FA
Hum Gene Ther; 2003 Dec; 14(18):1741-51. PubMed ID: 14670125
[TBL] [Abstract][Full Text] [Related]
9. Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins.
Becker JC; Pancook JD; Gillies SD; Mendelsohn J; Reisfeld RA
Proc Natl Acad Sci U S A; 1996 Apr; 93(7):2702-7. PubMed ID: 8610104
[TBL] [Abstract][Full Text] [Related]
10. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D
Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer.
Tahara H; Lotze MT
Gene Ther; 1995 Mar; 2(2):96-106. PubMed ID: 7719935
[TBL] [Abstract][Full Text] [Related]
12. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of antitumor activity of a single-chain interleukin-12 IgG3 antibody fusion protein (mscIL-12.her2.IgG3).
Peng LS; Penichet ML; Dela Cruz JS; Sampogna SL; Morrison SL
J Interferon Cytokine Res; 2001 Sep; 21(9):709-20. PubMed ID: 11576465
[TBL] [Abstract][Full Text] [Related]
14. Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo.
Lieschke GJ; Rao PK; Gately MK; Mulligan RC
Nat Biotechnol; 1997 Jan; 15(1):35-40. PubMed ID: 9035103
[TBL] [Abstract][Full Text] [Related]
15. Cloning and expression of murine IL-12.
Schoenhaut DS; Chua AO; Wolitzky AG; Quinn PM; Dwyer CM; McComas W; Familletti PC; Gately MK; Gubler U
J Immunol; 1992 Jun; 148(11):3433-40. PubMed ID: 1350290
[TBL] [Abstract][Full Text] [Related]
16. Antitumor efficacy of a human interleukin-12 expression plasmid demonstrated in a human peripheral blood leukocyte/human lung tumor xenograft SCID mouse model.
Hess SD; Egilmez NK; Shiroko J; Bankert RB
Cancer Gene Ther; 2001 May; 8(5):371-7. PubMed ID: 11477457
[TBL] [Abstract][Full Text] [Related]
17. The anti-human tumor effect and generation of human cytotoxic T cells in SCID mice given human peripheral blood lymphocytes by the in vivo transfer of the Interleukin-6 gene using adenovirus vector.
Tanaka F; Abe M; Akiyoshi T; Nomura T; Sugimachi K; Kishimoto T; Suzuki T; Okada M
Cancer Res; 1997 Apr; 57(7):1335-43. PubMed ID: 9102222
[TBL] [Abstract][Full Text] [Related]
18. A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity.
Peng LS; Penichet ML; Morrison SL
J Immunol; 1999 Jul; 163(1):250-8. PubMed ID: 10384123
[TBL] [Abstract][Full Text] [Related]
19. Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors.
Zhang N; Sadun RE; Arias RS; Flanagan ML; Sachsman SM; Nien YC; Khawli LA; Hu P; Epstein AL
Clin Cancer Res; 2007 May; 13(9):2758-67. PubMed ID: 17460060
[TBL] [Abstract][Full Text] [Related]
20. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
